Repository logo

Blood and immune development in human fetal bone marrow and Down syndrome.

Accepted version



Change log


Jardine, Laura 
Quiroga Londoño, Mariana  ORCID logo
Reynolds, Gary 


Haematopoiesis in the bone marrow (BM) maintains blood and immune cell production throughout postnatal life. Haematopoiesis first emerges in human BM at 11-12 weeks after conception1,2, yet almost nothing is known about how fetal BM (FBM) evolves to meet the highly specialized needs of the fetus and newborn. Here we detail the development of FBM, including stroma, using multi-omic assessment of mRNA and multiplexed protein epitope expression. We find that the full blood and immune cell repertoire is established in FBM in a short time window of 6-7 weeks early in the second trimester. FBM promotes rapid and extensive diversification of myeloid cells, with granulocytes, eosinophils and dendritic cell subsets emerging for the first time. The substantial expansion of B lymphocytes in FBM contrasts with fetal liver at the same gestational age. Haematopoietic progenitors from fetal liver, FBM and cord blood exhibit transcriptional and functional differences that contribute to tissue-specific identity and cellular diversification. Endothelial cell types form distinct vascular structures that we show are regionally compartmentalized within FBM. Finally, we reveal selective disruption of B lymphocyte, erythroid and myeloid development owing to a cell-intrinsic differentiation bias as well as extrinsic regulation through an altered microenvironment in Down syndrome (trisomy 21).



B-Lymphocytes, Bone Marrow, Bone Marrow Cells, Dendritic Cells, Down Syndrome, Endothelial Cells, Eosinophils, Erythroid Cells, Fetus, Granulocytes, Hematopoiesis, Humans, Immune System, Immunity, Myeloid Cells, Stromal Cells

Journal Title


Conference Name

Journal ISSN


Volume Title



Springer Science and Business Media LLC


All rights reserved
Medical Research Council (MR/M008975/1)
Wellcome Trust (107630/Z/15/Z)
Biotechnology and Biological Sciences Research Council (BB/P002293/1)
Wellcome Trust (206328/Z/17/Z)
Wellcome Trust (203151/Z/16/Z)
Medical Research Council (MR/S036113/1)
Medical Research Council (MC_PC_17230)
MRC (MR/W014556/1)
Wellcome Trust (221052/B/20/Z)
Wellcome Trust (215116/Z/18/C)
Is derived from: